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Background: Gut microbiota is regarded as one of the major factors involved in the control of body
weight. The antiobesity effects of ginseng and its main constituents have been demonstrated, but the
effects on gut microbiota are still unknown.
Methods: To investigate the effect of ginseng on gut microbiota, 10 obese middle-aged Korean women
took Panax ginseng extracts for 8 wk and assessment of body composition parameters, metabolic bio-
markers, and gut microbiota composition was performed using 16S rRNA gene-based pyrosequencing at
baseline and at 8 wk. Signiﬁcant changes were observed in body weight and body mass index; however,
slight changes were observed in gut microbiota. We divided the participants into two groups, the
effective and the ineffective weight loss groups, depending on weight loss effect, in order to determine
whether the antiobesity effect was inﬂuenced by the composition of gut microbiota, and the composition
of gut microbiota was compared between the two groups.
Results: Prior to ginseng intake, signiﬁcant differences of gut microbiota were observed between both at
phyla and genera and the gut microbiota of the effective and ineffective weight loss groups was segre-
gated on a principal coordinate analysis plot.
Conclusion: Results of this study indicate that ginseng exerted a weight loss effect and slight effects on
gut microbiota in all participants. In addition, its antiobesity effects differed depending on the compo-
sition of gut microbiota prior to ginseng intake.
opyright  2014, The Korean Society of Ginseng, Published by Elsevier. Open access under CC BY-NC-ND license. 1. Introduction
Ginseng (the root of Panax ginseng Meyer, Araliaceae) has been
used in herbal medicine as a general tonic for the promotion of
health in Asian countries, including Korea, China, and Japan for
1,000 years [1]. The pharmacological properties of ginseng are
attributed to ginsenosides, also referred to as steroid saponins,
which are found in extracts of ginseng [2]. The pharmacological
effects of ginseng extracts and ginsenosides have been reported to
show various biological activities in inﬂammation, immunology,
and cancer [3e5]. The effects of ginseng on obesity and metabolic
disease, such as hypertension, diabetes, and hyperlipidemia, have
also been reported [6e10].
Obesity is a serious health problem that has become prevalent in
developed countries in recent years and is a risk factor forn Medicine of Korean Medicine, Don
Ginseng, Published by Elsevier. Opemetabolic disease [11]. Recent studies have demonstrated a link
between diet-induced obesity and changes in the gut microbial
ecology, resulting in an increased capacity of the distal gut micro-
biota to promote host adiposity [12,13]. Animal and human studies
have revealed a remarkable microbial inﬂuence on host meta-
bolism, energy utilization and storage, and metabolic disease [14e
16]. Gut microbiota is regarded as one of the major etiological
factors involved in the control of body weight, so that drugs or
components that help to maintain balance in the composition of
the gut microbiota can increase the antiobesity effect [17,18].
Although the antiobesity effects of ginseng have been reported,
whether or not it has an effect on the gut microbiota is still un-
known. Other studies on ginseng-related gut microbiota have re-
ported that metabolic activity of ginsenoside Rb1 to compound
K (a metabolite of ginseng saponin) is variable between individuals,gguk University Ilsan Hospital, 814 Siksa-dong, Goyang, Gyeonggi-do, Korea.
n access under CC BY-NC-ND license. 
Fig. 1. High performance liquid chromatography analysis of Panax ginseng extracts. Peaks: (1) Rg1; (2) Rf; and (3) Rc.
Table 2
Changes of Anthropometric and Biochemical Measurement
Parameters Prior to After p
M.-Y. Song et al / Ginseng, obesity and gut microbiota 107depending on the composition of gut microbiota in particular
[19,20].
Therefore, this study was conducted to assess the effects of
ginseng on obesity and gut microbiota using pyrosequencing based
on the 16S rRNA gene. In addition, the difference of its antiobesity
effects depending on gut microbiota composition was also
investigated.
2. Materials and methods
2.1. Study participants and design
This study was approved by the Institutional Review Board of
Dongguk University Ilsan Hospital (Gyeonggi-do, Korea; approval
no. 2012-SR-25). Participants were recruited by advertisements in
the local newspaper or by posters in the hospital. For qualiﬁcation,
participants should be obese [body mass index (BMI) 25 kg/m2]
and female aged 40e60 yr. They must have been weight-stable
within 10% during the past 6 mo, and free from antibiotics, pro-
biotics, or any drugs that could impact their weight for the pastTable 1





BP BW WC Body composition
analysis
Visit 1 (wk 0) O O O O O O
Visit 2 (wk 2) O O O O
Visit 3 (wk 4) O O O O
Visit 4 (wk 6) O O O O
Visit 5 (wk 8) O O O O O O
BP, blood pressure; BW, body weight; WC, waist circumference.3 mo. Participants with weight-inﬂuencing diseases, including
hyper/hypothyroidism, heart diseases, psychogenic diseases, or
other chronic systemic diseases were excluded. Smokers or preg-
nant women conﬁrmed by a positive hCG screening test were also
excluded. Nineteen participants were recruited, and 10 of them
completed the study. The participants were asked not to change
their exercise or diet habits during the 8-wk clinical trial. During
the study, participants who failed to take<80% of the required dose
of medicine, retracted their consents due to inconvenience (per-
sonal choices), or refused to have communicationwith members of
the research staff were dropped from the study.
2.2. Herbal preparation
Panax ginseng extracts were manufactured and provided by
Korea Medicine Biofermentation Co., Ltd (Andong, Korea).Age 50.40  4.95
BW (kg) 71.39  4.95 70.33  5.38 0.042*
BMI (kg/m2) 28.35  2.00 27.87  1.97 0.031*
WC (cm) 94.08  7.12 92.50  7.08 0.058
Body fat percentage (%) 37.89  4.27 37.24  5.21 0.544
TC (mg/dL) 209.90  27.23 211.00  27.30 0.821
TG (mg/dL) 136.50  67.48 139.20  53.07 0.841
HDL (mg/dL) 56.80  14.54 56.20  13.81 0.853
Glucose (mg/dL) 108.10  13.30 113.60  13.15 0.100
Data are presented as mean  SD.
* p < 0.05.
BMI, bodymass index; BW, bodyweight; HDL, high-density lipoprotein-cholesterol;
TC, total cholesterol; TG, triglyceride; WC, waist circumference.
Table 3
Summary of Estimated Diversities Obtained from Pyrosequences
Sample Analyzed reads Normalized reads Observed OTUs Estimated OTUs (Chao1) Shannon diversity Good’s coverage
Prior to 1 1,866 1,866 336 1,728.13 3.67 0.86
2 2,923 2,000 340 3,087.25 3.20 0.85
3 2,753 2,000 243 1,743.23 2.96 0.90
4 5,354 2,000 246 1,103.37 3.68 0.91
5 4,863 2,000 350 1,988.45 3.89 0.87
6 2,485 2,000 227 595.88 3.63 0.93
7 3,320 2,000 179 485.71 3.01 0.94
8 3,334 2,000 213 717.79 3.38 0.93
9 4,503 2,000 427 3,647.56 4.32 0.83
10 5,070 2,000 218 784.25 3.37 0.92
After 1 2,056 2,000 372 1,440.03 4.14 0.87
2 2,262 2,000 343 2,893.88 3.38 0.85
3 2,953 2,000 244 1,544.20 2.96 0.90
4 4,922 2,000 297 1,394.29 3.49 0.89
5 5,137 2,000 522 3,800.79 4.65 0.79
6 4,345 2,000 415 1,555.36 4.21 0.85
7 3,209 2,000 229 913.00 3.65 0.92
8 2,417 2,000 96 255.00 2.59 0.97
9 3,510 2,000 159 366.83 3.29 0.96
10 6,329 2,000 163 649.77 2.47 0.94
OTU, operational taxonomic unit.
J Ginseng Res 2014;38:106e115108Quantities of the freeze-dried granulated extracts weighing 4 g
each were packed in paper medicine pockets. The medicines were
distributed to the participants per 2 wk at every visit. The partici-
pants were asked to take one packet two times/d. The herbal
medicines were distributed to the participants by the administra-
tive pharmacist in the dispensary of the hospital.Fig. 2. The phylum and genus composition of fecal bacteria were compared between prior t
phyla identiﬁed from pyrosequencing data is shown. (A) Phylum composition of fecal bact2.3. Ginsenosides analysis
Ginsenosides were determined using high performance liquid
chromatography (HP 1050, AGILENT, Santa Clara, CA, USA), the
analytical column was an Ultrasphere ODS (C18, 5 mm,
4.6 mm  250 mm, Shiseido, Tokyo, Japan). The two mobile phaseso and after treatment in a total of 10 participants. The relative abundance of dominant
eria. (B) Genus composition.
Fig. 3. Principal coordinate analysis (PCoA) plot in a total of 10 participants. The plot shows the clustering pattern depending degree of weight loss. The participants’ number and
body weight change are shown. EWG, effective weight loss group; IWG, ineffective weight loss group.
Table 4
Comparison of General Characteristics Between the Effective Weight Loss Group
(EWG) and Ineffective Weight Loss Group (IWG) at Baseline
Parameters EWG IWG p
Age (y) 53.25  5.06 49.25  4.65 0.182
BW (kg) 71.65  4.55 74.57  3.49 0.200
BMI (kg/m2) 28.83  2.83 28.57  0.95 0.887
TC (mg/dL) 207.75  18.66 209.67  33.84 0.926
TG (mg/dL) 111.75  55.99 187.00  67.51 0.199
HDL (mg/dL) 53.25  5.31 62.33  26.27 0.612
Glucose (mg/dL) 100.25  16.62 108.00  6.92 0.446
Data are presented as mean  SD.
BMI, body mass index; BW, body weight; HDL, high-density lipoprotein -choles-
terol; TC, total cholesterol; TG, triglyceride.
M.-Y. Song et al / Ginseng, obesity and gut microbiota 109were water (Samchun Chemical, Gyeonggi, Korea) and acetonitrile
(Samchun Chemical, Gyeonggi, Korea). The ﬂow rate was set at
0.4 mL/min and wavelength was 203 nm. Seventeen saponins (Rb2,
Rb3, Rc, Rd, Re, Rf, Rg1, Rg2S, Rg2R, Rg3S, Rg3R, Rh1, Rh2S, Rh2R, C-
K, F1, F2; SigmaeAldrich, St Louis, MO, USA) were used as standards
for this purpose. Rg1, Rf, and Rc were the main contents, the
retention time of Rg1 was 16.12 min, that of Rf was 19.18 min, and
that of Rc was 19.53 min. The concentration of Rg1 was 3.73%, that
of Rf was 3.57%, and that of Rc was 1.87% (Fig. 1).
2.4. Assessment
Progress of analytical measurements in the study is shown in
Table 1.The participants were asked to visit every 2nd wk. Blood
pressure, body weight, waist circumference, and body composition
were measured at every visit, and blood analysis and stool analysis
were checked on the 1st visit day (wk 0) and last day (wk 8).
2.5. Physical examination and anthropometry
Blood pressure and heart rate were measured using an auto-
matic digital sphygmomanometer. Wearing a hospital gown, body
weight and height were measured to the nearest 0.1 kg and 0.5 cm,
respectively. Waist circumference was measured three times ac-
cording to the World Health Organization method [21] by the same
observer.
2.6. Body composition analysis
Body composition was measured at every visit using the
bioelectrical impedance analysis method (InBody 3.0; Biospace,
Seoul, Korea). This device measures impedance through eight
tactile electrodes placed on palms, thumbs, heels, and soles. Eachparticipant stood upright, stepping onto the foot electrodes and
loosely gripping the pipe-shaped hand electrodes with arms held
vertically. Lean body mass, body mass index, and percent fat were
measured and recorded.
2.7. Blood chemistry
Blood tests including fasting glucose, high-density lipoprotein-
cholesterol, triglyceride, and total cholesterol were performed prior
to the start of the experiment and 8 wk later. At baseline, partici-
pants with high fasting blood glucose (>140 mg/dL) or possible
liver problems (aspartate aminotransferase or alanine amino-
transferase >100 IU/L) were excluded.
2.8. Pyrosequencing
The participants were asked to bring their stool samples on the
1st visit day (wk 0) and last day (wk 8) in the stool-sampling
J Ginseng Res 2014;38:106e115110container. The fresh human stools were collected and immediately
stored at e70C. Genomic DNA were extracted from fecal samples
of participants using a Fast DNA SPIN extraction kit (MP Bio-
medicals, Santa Ana, CA, USA), and fragments of the 16S rRNA gene
(V1eV3) were ampliﬁed from the extracted DNA. The ampliﬁca-
tions were performed according to previous reports using aFig. 4. Rarefaction curves of (A) effective weight loss group (EWG) and (B) ineffective weigh
obtaining a normalized read size in each sample.barcoded fusion primer [22,23] using a C1000 Touch thermal cycler
(Bio-Rad, Hercules, CA, USA). The ampliﬁed products were visual-
ized on 2% agarose gel electrophoresis using the Gel Doc system
(Bio-Rad). Amplicons were puriﬁed using the QIA quick PCR puri-
ﬁcation kit (Qiagen, Valencia, CA, USA) and quantiﬁed using the
PicoGreen dsDNA Assay kit (Invitrogen, Carlsbad, CA, USA).t loss group (IWG) samples were compared. The rarefaction curves were obtained after
Table 5
Comparison of Gut Microbiota Between the EWG and IWG at Baseline
Gut microbiota (%) EWG (%) IWG (%) p
Phylum Firmicutes 84.25  10.33 68.44  5.20 0.034*
Actinobacteria 7.29  7.21 28.46  6.81 0.034*
Bacteroidetes 3.42  2.74 1.48  1.71 0.480
Proteobacteria 0.07  0.06 1.54  1.73 0.034*
Tenericutes 4.86  4.90 0.01  0.01 0.142
Verrucomicrobia 0.13  0.27 0.07  0.08 0.172
Genus Blautia 23.78  23.80 14.06  8.61 0.724
Biﬁdobacterium 5.75  5.40 25.43  9.74 0.034*
Faecalibacterium 3.49  3.82 7.13  3.42 0.289
Clostridium_g4 3.97  3.26 3.86  5.84 1.000
Eubacterium_g5 12.99  7.60 4.20  3.96 0.480
Anaerostipes 12.99  7.60 1.87  1,48 0.157
Bacteroides 1.87  1.48 1.00  1.48 0.289
Clostridium 1.09  1.03 1.80  2.73 0.724
Collinsella 1.01  1.80 2.38  4.13 1.000
Lactobacillus 0.51  0.63 7.08  12.73 0.724
Dorea 4.08  4.73 1.74  1.26 0.480
Subdoligranulum 1.49  1.50 1.40  1.42 0.858
Lachnospiraceae_uc 1.57  1.01 1.29  0.54 0.480
Dialister 8.32  15.90 0.10  0.09 0.714
Oscillibacter 2.53  2.34 1.17  1.14 0.212
Roseburia 2.53  2.34 1.17  1.14 0.289
Escherichia 0.00  0.00 0.89  0.57 0.019*
Clostridium_g23 0.00  0.00 0.17  0.21 0.019*
Data are presented as mean  SD.
* p < 0.05.
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were pooled and puriﬁed using the AMPure bead kit (Agencourt
Bioscience, Beverly, MA, USA) and then ampliﬁed on sequencing
beads by emulsion PCR. Sequencing reactions were performed us-
ing a Roche/454 GS Junior system (454 Life Sciences, Branford, CT,
USA) following the manufacturer’s instructions.
2.9. Sequence data analysis
Obtained sequences were sorted according to their unique
barcode in the demultiplexing step, and low quality reads (average
quality score <25 or read length <300 bp) were removed for
further analysis. Primer sequences were trimmed by pairwise
sequence alignment and the hmm-search program of the HMMER
3.0 package [24]. To modify sequencing errors, representative se-
quences in clusters of trimmed sequences were chosen for taxon-
omy identiﬁcation. Each read was characterized by their taxonomic
positions according to the highest pairwise similarity among the
top ﬁve BLASTN hits against the EzTaxon-e database [25]. Chimera
sequences were removed by UCHIME [26]. Various read numbers in
samples were normalized by random subsampling, and the di-
versity indices were calculated using the mothur program [27].
Pyrosequencing reads obtained from this study are available in the
European Molecular Biology Laboratory Sequence Read Archive
database under study number PRJEB4531 [28].
2.10. Statistical analysis
Results are presented as mean  standard deviation. Compari-
son of prior to and after treatment was performed using paired t
test and Wilcoxon signed-rank test and the two groups divided
according to weight loss effect were compared using the Manne
Whitney U test. Values of p < 0.05 were considered statistically
signiﬁcant. All analyses were performed using SPSS version 15.0 for
Windows (SPSS Inc., Chicago, IL, USA).
3. Results and discussion
3.1. Anthropometric and biochemical changes
Differences of gut microbial communities are related to gender
and age [29,30], therefore we limited our inclusion criteria to a
speciﬁc gender and the participants were middle-aged (40e59 yr)
women. A total of 10 participants completed the trial; their general
characteristics are shown in Table 2. Age was 50.40  4.95 yr and
body weight and BMI were 71.39 4.95 kg and 28.35 2.00 kg/m2,
respectively.
After ginseng intake, signiﬁcant decreases were observed in
weight and BMI, with difference of e1.06  1.41 kg
and 0.48  0.59 kg/m2, respectively. However, no signiﬁcant
decreasewas observed inwaist circumference, body fat percentage,
high-density lipoprotein-cholesterol, triglyceride, total cholesterol,
and glucose. In contrast to this result, the effects of ginseng, gin-
senosides, or compound K on antiobesity have been reported as
lowering cholesterol and controlling blood glucose via inhibition of
lipid accumulation in adipocyte and increase of phosphorylation of
insulin receptor substrate-1, Akt, membranous glucose transporter
4 in muscle [7e9]. However, there was no signiﬁcant effect on
obesity related parameters in this study. No effects of ginseng on
these parameters were reported in randomized controlled studies
for healthy obese participants during 12 wk, [31,32]. A longer
duration of taking ginseng might be needed to conﬁrm signiﬁcant
effects for human beings. Different bacterial ginsenoside-hydro-
lyzing effects between humans and experimental mice [33] andindividual difference of metabolic ability to ginseng could be a
reason for this result.
3.2. Analysis of gut microbiota
Weperformed pyrosequencing for analysis of the gutmicrobiota
of prior to and after in ginseng treated participants. Bacterial
richness and diversity obtained from pyrosequencing after
normalization of reads number are shown in Table 3. A total of
73,611 sequences were obtained and analyzed, and the normalized
read number of each sample for comparison of diversity indices
was 2,000. Good’s coverage of samples was over 80%, except for the
after treatment sample of Participant 5. Increased Shannon di-
versity indices were detected in the after treatment sample
compared to the prior to treatment sample for Participants 1, 2, 5, 6,
and 7, whereas deceased indices were detected for samples of
Participants 4, 8, 9, and 10.
Predominant phyla in average community compositions were
Firmicutes, Actinobacteria, and Bacteroidetes, and no signiﬁcant
change in phylum level was observed between prior to and after.
Selected genera having over 1% proportion of median value were
compared. Themain dominants were changed after ginseng intake;
those prior to intake were genera of Blautia, Biﬁdobacterium, and
Anaerostipes whereas those after intake were Biﬁdobacterium,
Blautia, and Faecalibacterium, in order of abundance (Fig. 2). Sig-
niﬁcant change was observed only in the relative abundance of
Anaerostipes; prior to was 6.70  3.35%, and after was 3.11  3.24%
(data not shown).
3.3. Comparison of gut microbiota between the effective and
ineffective weight loss groups
To express the pharmacological actions of ginseng saponins, it is
presumed that ginsenosides, the main constituent of ginseng, must
be metabolized by human intestinal microbes after being taken
orally [34]. The ginsenoside Rb1 in orally administered ginseng is
metabolized to compound K by gut microbiota prior to its ab-
sorption into the blood. Beta-glucosidase, produced by intestinal
J Ginseng Res 2014;38:106e115112microbiota, plays an important role in the pharmacological actions
of ginsenoside and the components of ginseng; it is the represen-
tative ginsenoside-transforming enzyme. This enzyme activity of
gut microbiota varies signiﬁcantly between individuals, so that theFig. 5. The phylum and genus compositions of fecal bacteria were compared between prior
loss group (IWG). The relative abundance of dominant phyla identiﬁed from pyrosequencing
right panels). (A) Phylum composition of fecal bacteria prior to ginseng intake. (B) Genus pmetabolizing activities of ginsenoside Rb1inindividuals are
signiﬁcantly different [19]. People with different levels of ginse-
noside Rb1 degradation to compound K had different gut micro-
biota [20].to and after treatment in the effective weight loss group (EWG) and ineffective weight
data is shown (individual samples are on the left panels and pooled samples are on the
rior to intake. (C) Phylum after intake. (D) Genus after intake.
Fig. 5. (continued).
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inﬂuenced by the composition of gut microbiota, we analyzed bac-
terial communities of all participants at the baseline using principal
coordinate analysis (PCoA). In the PCoA plot, gut microbiota of eachmemberwas clusteredaccording to thedegreeofweight loss (Fig. 3).
The groups were designated as: the effective weight loss group
(EWG;Participants 1, 2, 5, and6;weight change,2.40.38kg); and
ineffectiveweight loss group (IWG; Participants 3, 4, and 10; weight
Table 6
Changes of Gut Microbiota Between Effective Weight Loss Group (EWG) and Inef-
fective Weight Loss Group (IWG) Samples After Ginseng Intake
Gut microbiota (%) EWG (%) IWG (%) p
Phylum Firmicutes 0.20  16.06 6.69  23.82 0.724
Actinobacteria 0.57  10.43 8.59  25.34 0.724
Bacteroidetes 0.41  3.77 0.77  1.57 0.724
Proteobacteria 0.21  0.25 1.21  1.01 0.034*
Tenericutes 0.12  8.42 0.01  0.01 0.714
Verrucomicrobia 0.19  0.36 0.03  0.28 0.067
Genus Blautia 1.88  6.48 1.25  9.70 1.000
Biﬁdobacterium 0.36  10.11 10.00  24.39 0.289
Faecalibacterium 2.52  5.55 4.14  5.94 0.157
Clostridium_g4 0.02  0.93 1.10  2.69 0.480
Eubacterium_g5 1.03  4.11 3.16  7.19 0.724
Anaerostipes 7.03  4.95 2.36  3.46 0.157
Bacteroides 1.18  3.02 0.64  1.36 0.157
Clostridium 0.43  1.20 1.75  2.64 0.289
Collinsella 0.12  0.26 1.55  2.75 0.593
Lactobacillus 0.32  0.71 2.88  4.45 0.289
Dorea 0.38  2.76 0.47  1.34 0.480
Subdoligranulum 0.23  1.00 2.57  5.14 0.858
Lachnospiraceae_uc 0.80  0.94 0.34  1.09 0.289
Dialister 0.10  0.17 6.64  11.54 0.372
Oscillibacter 6.21  12.86 0.05  0.47 0.372
Roseburia 0.29  2.88 0.07  1.25 0.480
Data are presented as mean  SD.
* p < 0.05.
J Ginseng Res 2014;38:106e115114change, 0.630.64kg). Although therewasno signiﬁcant difference
in general characteristics such as age andobesity related parameters
(Table 4), different gut microbiota was observed between groups.
The rarefaction curves showed the difference of gut microbiota be-
tween the two groups (Fig. 4). The richness of bacterial communities
obtained from EWGwas relatively higher than that of IWG. Phyla ofFig. 6. Principal coordinate analysis plot. The plot shows the clustering pattern between th
weighted pairwise Fast UniFrac analysis. , the community of EWG in the prior to ginseng i
intake; , that of IWG in the after ginseng intake. Unbroken circles indicate grouping of the
ginseng intake.Firmicutes, Actinobacteria, Tenericutes, and Bacteroidetes were
predominant in EWG samples of prior to ginseng intakes, whereas
Firmicutes, Actinobacteria, and Proteobacteria were dominant in
IWG samples (Table 5, Fig. 5A). Relative abundances of Actino-
bacteria and Proteobacteria in EWG were lower than those in IWG,
whereas phyla of Tenericutes, Bacteroidetes, and Firmicutes were
more abundant in the EWG than IWG. Furthermore the relative
abundances of Firmicutes, Actinobacteria and Proteobacteria were
signiﬁcantly different between both groups. These results partly
correspondwith the earlier one. Sampleswith fecal activity potently
metabolizing ginsenoside Rb1 to compound K had lower levels of
Proteobacteria and higher levels of Tenericutes and Bacteriodetes
than in samples with fecal activity non-metabolizing ginsenoside
Rb1 to compound K [20]. For detailed microbial composition, we
analyzed the composition of genera, it had also noteworthy differ-
ences between groups (Table 5, Fig. 5B). The three predominant
genera in EWGwere Blautia, Anaerostipes, andOscillibacter, whereas
those in IWG were Biﬁdobacterium, Blautia, and Clostridium_g4. The
relative abundances of Anaerostipes and Eubacterium_g5 were
increased in EWG, whereas that of Lactobacillus was increased in
IWG. Furthermore, the relative abundance of Biﬁdobacterium,
Escherichia, and Clostridium_g23 in EWG were signiﬁcantly lower
than those in IWG. However, the genera that had signiﬁcant differ-
ences between the groups (Clostridiales_uc_g, Oscillibacter, Rumi-
nococcus, Holdemania, and Sutterella) were not consistent with a
previous study [20]. Individual variations of gut microbiota [35] can
generate these different results, so it is not easy to compare directly
between the two limited sample sized studies.
The antiobesity effect of ginseng could work differently
depending on gut microbiota composition as explained above. We
also wanted to know whether ginseng could make changes of gute effective weight loss group (EWG) and ineffective weight loss group (IWG) based on
ntake; , that of EWG in the after ginseng intake, , that of IWG in the prior to ginseng
communities in the prior to ginseng intake and broken circles indicate that in the after
M.-Y. Song et al / Ginseng, obesity and gut microbiota 115microbial composition. Therefore, we investigated changes of mi-
crobial composition after ginseng intake. Each group showed
changes in microbial composition; the threemain dominant genera
of EWGwere changed to Blautia, Faecalibacterium, and Anaerostipes,
and those of IWG were changed to Biﬁdobacterium, Blautia, and
Clostridium at the genus level (Fig. 5C and D). However, neither
group showed statistically signiﬁcant changes at the phylum or
genus level (data not shown). In addition, we compared the
changes of gut microbiota after ginseng treatment between the two
groups; only the relative composition of Proteobacteria had sig-
niﬁcant change (Table 6).
The comparisons of bacterial communities between prior to and
after ginseng intake in both groups were analyzed by PCoA plot
(Fig. 6). Prior to ginseng intake, bacterial communities were segre-
gated depending onweight loss effect, but therewas no remarkable
changeof bacterial communities inbothgroupsafter ginseng intake.
This indicates that the inﬂuence of ginseng intakes on bacterial
community was not considerable, however the compositions of gut
bacteria could determine whether weight loss is effective or not.
Ginseng exerted a weight loss effect and slight effects on gut
microbiota in all participants. It is an important result that its an-
tiobesity effects differed depending on the composition of gut
microbiota prior to ginseng intake. The biotransformation activity
from ginsenoside-Rb1 to compound K was signiﬁcantly different
among individuals [36], and intestinal bacterial metabolism of
ginseng is dependent on the composition of gut microbiota [19,20].
Therefore, a single ginsenoside or a ginseng extract may lead to
different effects among participants [33]. However, we did not
analyze the biotransformation activity ginsenoside to compound K,
for example, so supplemental studies are necessary to conﬁrm the
metabolism of ginseng by gut microbiota for antiobesity.
There were other limitations in this study including: no
controlled study, a limited number of participants, and a limited
study period. Therefore, the present study can be considered
explorative research, which can motivate a full-scaled one. How-
ever, it was the ﬁrst trial to assess the effects of ginseng on obesity
and gut microbiota as well different weight loss effects depending
on the composition of gut microbiota.
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